申请人:Janssen Pharmaceutica, N.V.
公开号:US05773433A1
公开(公告)日:1998-06-30
This invention concerns the compounds of formula (I), the pharmaceutically acceptable salts and stereoisomeric forms thereof, and also the N-oxide forms thereof. ##STR1## wherein: R.sup.1 and R.sup.2 each independently are hydrogen; C.sub.1-6 alkyl; C.sub.1-6 alkylcarbonyl; trihalomethylcarbonyl; C.sub.1-6 alkyl substituted with hydroxy, C.sub.1-6 alkyloxy, carboxyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkyloxycarbonyl or aryl; or R.sup.1 and R.sup.2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; R.sup.3 to R.sup.10 each independently are hydrogen, halo, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, carboxyl, nitro, amino, mono- or di(C.sub.1-6 alkyl)amino, C.sub.1-6 alkylcarbonylamino, aminosulfonyl, mono- or di(C.sub.1-6 alkyl)-aminosulfonyl, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkyloxycarbonyl; R.sup.11 is hydrogen, C.sub.1-6 alkyl, or trifluoromethyl; R.sup.12 is hydrogen, C.sub.1-6 alkyl, cyano, or trifluoromethyl; n is zero to 6; and X is O, S, S(.dbd.O) or S(.dbd.O).sub.2. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.
这项发明涉及公式(I)的化合物,其药学上可接受的盐和立体异构体形式,以及其N-氧化物形式。其中:R.sup.1和R.sup.2各自独立地是氢;C.sub.1-6烷基;C.sub.1-6烷基羰基;三卤甲基羰基;C.sub.1-6烷基取代羟基,C.sub.1-6烷氧基,羧基,C.sub.1-6烷基羰氧基,C.sub.1-6烷氧羰基或芳基;或R.sup.1和R.sup.2连同它们连接的氮原子一起可能形成吗啡啉环或可选择取代的杂环;R.sup.3至R.sup.10各自独立地是氢,卤素,氰基,羟基,三氟甲基,三氟甲氧基,羧基,硝基,氨基,单或双(C.sub.1-6烷基)氨基,C.sub.1-6烷基羰氨基,氨基磺酰基,单或双(C.sub.1-6烷基)-氨基磺酰基,C.sub.1-6烷基,C.sub.1-6烷氧基,C.sub.1-6烷基羰基,C.sub.1-6烷氧羰基;R.sup.11是氢,C.sub.1-6烷基或三氟甲基;R.sup.12是氢,C.sub.1-6烷基,氰基或三氟甲基;n为零至6;X为O,S,S(.dbd.O)或S(.dbd.O).sub.2。公式(I)的化合物可用作治疗或预防中枢神经系统疾病、心血管疾病或消化系统疾病的治疗剂。